CompletedPhase 4

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

United States, Canada66 participantsStarted 2009-03

Plain-language summary

The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or Female * At least 50 years of age * In good general health Exclusion Criteria: * Any ocular surgery or use of topical antibiotics or antiseptics in either eye within the last 3 months * Use of topical steroids, or non-steroidal anti inflammatory drugs in either eye within 30 days of Baseline (or anticipated during the study) * Use of lid scrubs within 7 days of Baseline in either eye (or anticipated use during the study)

What they're measuring

Percentage of Subjects With Strain Resistance of the Conjunctiva as Determined by Minimum Inhibitory Concentration (MIC) at Day 14

Timeframe: Day 14

Trial details

NCT IDNCT00874887

SponsorAllergan

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-09

Results submitted2011-11-16

View on ClinicalTrials.gov More Anti-biotic Resistance trials